Karo Pharma (DB:KA6N) - Aktienkurs, Nachrichten und Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

KA6N Aktienübersicht

Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally.

Über das Unternehmen

KA6N grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	1/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Interest payments are not well covered by earnings

Earnings have declined by 46.5% per year over past 5 years

Shareholders have been diluted in the past year

Karo Pharma AB (publ) Wettbewerber

Bayer

XTRA:BAYN

€25.7b

Merck KGaA

XTRA:MRK

€68.5b

Dermapharm Holding

XTRA:DMP

€1.9b

PharmaSGP Holding

XTRA:PSG

€280.6m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Karo Pharma
Historische Aktienkurse
Aktueller Aktienkurs	US$5.44
52-Wochen-Hoch	US$6.00
52-Wochen-Tief	US$4.57
Beta	0.10
11 Monat Veränderung	0.37%
3 Monate Veränderung	-1.81%
1 Jahr Veränderung	-2.68%
33 Jahre Veränderung	48.31%
5 Jahre Veränderung	40.68%
Veränderung seit IPO	-99.42%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	KA6N	DE Pharmaceuticals	DE Markt
7D	0.7%	-5.0%	0.4%
1Y	-2.7%	-17.0%	3.9%

Rendite im Vergleich zur Industrie: KA6N exceeded the German Pharmaceuticals industry which returned -8.8% over the past year.

Rendite vs. Markt: KA6N exceeded the German Market which returned -16.6% over the past year.

Preisvolatilität

Is KA6N's price volatile compared to industry and market?
KA6N volatility
KA6N Average Weekly Movement	1.9%
Pharmaceuticals Industry Average Movement	5.7%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.5%
10% least volatile stocks in DE Market	2.5%

Stabiler Aktienkurs: KA6N has not had significant price volatility in the past 3 months.

Volatilität im Zeitverlauf: KA6N's weekly volatility (2%) has been stable over the past year.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1987	225	Christoffer Lorenzen	www.karopharma.com

Karo Pharma AB (publ)'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Karo Pharma im Vergleich zum Marktanteil des Unternehmens?
KA6N grundlegende Statistiken
Marktanteil	€15.95b
Gewinn(TTM)	-€189.85m
Umsatz(TTM)	€3.47b

0.0x

Kurs-Umsatz-Verhältnis

0.0x

Kurs-Gewinn-Verhältnis

Ist KA6N zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
KA6N Gewinn- und Verlustrechnung (TTM)
Einnahmen	SEK 3.47b
Kosten der Einnahmen	SEK 1.50b
Bruttogewinn	SEK 1.96b
Sonstige Ausgaben	SEK 2.15b
Umsatz	-SEK 189.85m

Zuletzt gemeldete Gewinne

Jun 30, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.69
Bruttomarge	56.67%
Nettogewinnspanne	-5.48%
Schulden/Eigenkapital-Verhältnis	104.8%

Wie hat sich KA6N auf lange Sicht entwickelt?

Historische Performance und Vergleiche

This company listing is no longer active

KA6N Aktienübersicht

Belohnungen

Risikoanalyse

Karo Pharma AB (publ) Wettbewerber

XTRA:BAYN

€25.7b

XTRA:MRK

€68.5b

XTRA:DMP

€1.9b

XTRA:PSG

€280.6m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million.

Nasdaq Approves Karo Pharma's Application for De-Listing

Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (publ) (OM : KARO) for SEK 2.2 billion.

Karo Pharma AB (publ) (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT).

Karo Pharma AB (publ) to Report Fiscal Year 2021 Final Results on Apr 12, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Recent updates

Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million.

Nasdaq Approves Karo Pharma's Application for De-Listing

Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (publ) (OM : KARO) for SEK 2.2 billion.

Karo Pharma AB (publ) (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT).

Karo Pharma AB (publ) to Report Fiscal Year 2021 Final Results on Apr 12, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Karo Pharma AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Karo Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022

Karo Pharma AB (publ) completed the acquisition of Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others.

Karo Pharma AB (publ) entered into an agreement to acquire Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others for €300 million.

Third quarter 2021 earnings released: EPS kr0.26 (vs kr0.013 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.095 loss per share (vs kr0.11 profit in 2Q 2020)

Evolan Pharma AB acquired Portfolio Consisting of 12 Brands from Karo Pharma AB (publ) (OM:KARO).

Independent Chairman of the Board Bo Hansen has left the company

First quarter 2021 earnings released: EPS kr0.24 (vs kr0.39 in 1Q 2020)

Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)

Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)

Karo Pharma AB (publ), Annual General Meeting, Apr 21, 2021

Karo Pharma AB (publ) (OM:KARO) acquired European OTC brand portfolio of Teva Pharmaceutical Industries Limited (NYSE:TEVA) for €84 million.

New 90-day low: €4.81

New 90-day low: €5.08

Karo Pharma AB (publ) to Report First Half, 2021 Results on Jul 22, 2021

New 90-day low: €5.38

New 90-day low: €5.87

J2L Holding AB agreed to acquire Swereco AB from Karo Pharma AB (publ) (OM:KARO) for SEK 150 million.

Third quarter 2020 earnings released: kr0.013 loss per share

Third quarter earnings released

EQT VIII, a fund managed by EQT Partners completed the acquisition of 66.5% stake in Karo Pharma AB (publ) (OM:KARO) for SEK 4.1 billion.

Karo Pharma AB (publ) (OM:KARO) acquired remaining Pevaryl® brand portfolio from Cilag GmbH International for €58 million.

Karo Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 18, 2021

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Karo Pharma AB (publ)'s Grundlagenzusammenfassung

0.0x

0.0x

Erträge &amp; Einnahmen

Erträge & Einnahmen